Table 2 Novel 3D right ventricular parameters and volumes depending on the occurrence of adverse postoperative outcomes (APOs).
Retrospective cohort (n = 439) | p-value | Prospective cohort (n = 128) | p-value | |||
|---|---|---|---|---|---|---|
no APOs (n = 231) | APOs (n = 208) | no APOs (n = 100) | APOs (n = 28) | |||
Global metrics | ||||||
RVEDV, ml | 146.2 ± 46.5 | 152.9 ± 51.7 | 0.153 | 130.7 ± 31.4 | 152.3 ± 47.3 | 0.005 |
RVEDVi, ml/m² | 75.7 ± 22.5 | 77.6 ± 24.8 | 0.403 | 66.8 ± 16.6 | 75.2 ± 19.5 | 0.024 |
RVESV, ml | 88.9 ± 35.4 | 98.3 ± 39.1 | 0.009 | 72.8 ± 24.0 | 96.9 ± 42.2 | < 0.001 |
RVESVi, ml/m² | 46.0 ± 17.7 | 49.8 ± 18.9 | 0.032 | 37.0 ± 11.7 | 47.3 ± 17.1 | < 0.001 |
RVEF, % | 39.8 ± 9.3 | 36.4 ± 9.3 | < 0.001 | 44.9 ± 8.0 | 37.9 ± 10.4 | < 0.001 |
RV GLS, % | -14.8 ± 4.7 | -12.7 ± 4.6 | < 0.001 | -17.3 ± 4.1 | -14.3 ± 4.8 | 0.001 |
RV GCS, % | -14.4 ± 5.4 | -13.3 ± 5.1 | 0.032 | -17.5 ± 4.7 | -14.3 ± 4.9 | 0.002 |
RV GAS, % | -26.5 ± 7.5 | -23.8 ± 7.0 | < 0.001 | -30.0 ± 6.3 | -25.1 ± 7.8 | 0.001 |
Motion decomposition metrics | ||||||
LEF, % | 16.3 ± 5.5 | 14.1 ± 5.5 | < 0.001 | 17.5 ± 5.2 | 14.9 ± 5.8 | 0.024 |
LEF/RVEF | 0.41 ± 0.11 | 0.39 ± 0.13 | 0.056 | 0.39 ± 0.09 | 0.39 ± 0.10 | 0.941 |
AEF, % | 17.3 ± 6.1 | 15.4 ± 5.7 | 0.001 | 22.1 ± 6.3 | 17.7 ± 7.3 | 0.002 |
AEF/RVEF | 0.43 ± 0.11 | 0.42 ± 0.11 | 0.322 | 0.49 ± 0.10 | 0.46 ± 0.13 | 0.121 |
REF, % | 15.9 ± 8.0 | 14.6 ± 8.1 | 0.116 | 19.5 ± 7.5 | 15.5 ± 7.1 | 0.012 |
REF/RVEF | 0.39 ± 0.16 | 0.39 ± 0.17 | 0.952 | 0.43 ± 0.14 | 0.40 ± 0.13 | 0.360 |
